Skip to content

The Effect of prethrombolytic Cyclosporine A injection on Acute Anterior ST-Elevation Myocardial Infarction Outcome.

The Effect of prethrombolytic Cyclosporine A injection on Acute Anterior ST-Elevation Myocardial Infarction Outcome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138807052474N2
Enrollment
100
Registered
2010-01-09
Start date
2009-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. Acute transmural myocardial infarction of anterior wall

Interventions

Intervention 1: Cyclosporine 2.5 mg/kg in intervention group (pre thrombolytic). Intervention 2: Normal saline in control group (pre thrombolytic).
Treatment - Drugs
Cyclosporine 2.5 mg/kg in intervention group (pre thrombolytic)
Normal saline in control group (pre thrombolytic)

Sponsors

Research vice-chancellor of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : in patients with 18 years of age or older, presence of ischemic chest pain and ST segment elevation of 1 mm or more in at least two contiguous leads of anterior region, who admits in primary six hours of symptoms onset and candidate for thrombolytic therapy Exclusion criteria : cardiac arrest, primary VF, prior MI, uncontrolled HTN, known hypersensitivity to cyclosporine, known renal failure or a serum creatinine level of 120 mol per liter (1.36 mg per deciliter) or more at admission, liver failure, and women who were pregnant or who were of childbearing age and were not using contraception, any disorder that is associated with immunologic dysfunction e.g., cancer, lymphoma, a positive serologic test for the human immunodeficiency virus, or hepatitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
LVEF. Timepoint: 1st day & predischarge. Method of measurement: echocardiography.;Incidence of Heart Failure. Timepoint: During admission. Method of measurement: Basal pulmonary rales , lasix using, chest XRAY.;Incidence of Arrhythmia. Timepoint: During admission. Method of measurement: ECG monitoring.

Secondary

MeasureTime frame
All cause mortality rate. Timepoint: in hospital & 6 month later. Method of measurement: patient documents & calling.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Toluey Khormazard

Tabriz University of Medical Sciences

drmtoluey@yahoo.com+98 914 301 8779

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026